BridgeBio’s oncology spinout must stand out from the crowd
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
The numerical survival benefit versus Keytruda underperform’s Merck’s phase 3 study, but there’s a possible reason for that.